nodes	percent_of_prediction	percent_of_DWPC	metapath
Idarubicin—Epirubicin—thyroid cancer	0.155	0.52	CrCtD
Idarubicin—Doxorubicin—thyroid cancer	0.144	0.481	CrCtD
Idarubicin—Anthracyclines—Epirubicin—thyroid cancer	0.125	0.341	CiPCiCtD
Idarubicin—Anthracyclines—Doxorubicin—thyroid cancer	0.116	0.316	CiPCiCtD
Idarubicin—Topoisomerase Inhibitors—Epirubicin—thyroid cancer	0.0654	0.178	CiPCiCtD
Idarubicin—Topoisomerase Inhibitors—Doxorubicin—thyroid cancer	0.0605	0.165	CiPCiCtD
Idarubicin—Valrubicin—Epirubicin—thyroid cancer	0.0333	0.173	CrCrCtD
Idarubicin—Daunorubicin—Epirubicin—thyroid cancer	0.0333	0.173	CrCrCtD
Idarubicin—Doxorubicin—Epirubicin—thyroid cancer	0.0333	0.173	CrCrCtD
Idarubicin—TOP2A—Epirubicin—thyroid cancer	0.0316	0.287	CbGbCtD
Idarubicin—Epirubicin—Doxorubicin—thyroid cancer	0.0308	0.16	CrCrCtD
Idarubicin—Daunorubicin—Doxorubicin—thyroid cancer	0.0308	0.16	CrCrCtD
Idarubicin—Valrubicin—Doxorubicin—thyroid cancer	0.0308	0.16	CrCrCtD
Idarubicin—ABCC1—Vandetanib—thyroid cancer	0.0255	0.231	CbGbCtD
Idarubicin—ABCC1—Epirubicin—thyroid cancer	0.0175	0.159	CbGbCtD
Idarubicin—TOP2A—Doxorubicin—thyroid cancer	0.0168	0.153	CbGbCtD
Idarubicin—ABCC1—Doxorubicin—thyroid cancer	0.00932	0.0846	CbGbCtD
Idarubicin—CYP2C9—Sorafenib—thyroid cancer	0.00382	0.0347	CbGbCtD
Idarubicin—CYP2D6—Sorafenib—thyroid cancer	0.00349	0.0317	CbGbCtD
Idarubicin—CYP2D6—Doxorubicin—thyroid cancer	0.00212	0.0192	CbGbCtD
Idarubicin—Acral erythema—Epirubicin—thyroid cancer	0.00112	0.0369	CcSEcCtD
Idarubicin—Radiation recall reaction (dermatologic)—Sorafenib—thyroid cancer	0.00112	0.0367	CcSEcCtD
Idarubicin—Recall phenomenon—Sorafenib—thyroid cancer	0.00106	0.0347	CcSEcCtD
Idarubicin—Acral erythema—Doxorubicin—thyroid cancer	0.00104	0.0341	CcSEcCtD
Idarubicin—Radiation injury—Epirubicin—thyroid cancer	0.000646	0.0212	CcSEcCtD
Idarubicin—Pericarditis—Vandetanib—thyroid cancer	0.000628	0.0206	CcSEcCtD
Idarubicin—Radiation injury—Doxorubicin—thyroid cancer	0.000598	0.0196	CcSEcCtD
Idarubicin—Palmar-plantar erythrodysaesthesia syndrome—Epirubicin—thyroid cancer	0.000588	0.0193	CcSEcCtD
Idarubicin—Thromboembolism—Sorafenib—thyroid cancer	0.000577	0.0189	CcSEcCtD
Idarubicin—Palmar-plantar erythrodysaesthesia syndrome—Doxorubicin—thyroid cancer	0.000544	0.0178	CcSEcCtD
Idarubicin—Mucosal inflammation—Vandetanib—thyroid cancer	0.000491	0.0161	CcSEcCtD
Idarubicin—Radiation recall reaction (dermatologic)—Epirubicin—thyroid cancer	0.000413	0.0135	CcSEcCtD
Idarubicin—Gastrointestinal toxicity—Epirubicin—thyroid cancer	0.000413	0.0135	CcSEcCtD
Idarubicin—Recall phenomenon—Epirubicin—thyroid cancer	0.000391	0.0128	CcSEcCtD
Idarubicin—Gastrointestinal toxicity—Doxorubicin—thyroid cancer	0.000382	0.0125	CcSEcCtD
Idarubicin—Radiation recall reaction (dermatologic)—Doxorubicin—thyroid cancer	0.000382	0.0125	CcSEcCtD
Idarubicin—Tachyarrhythmia—Epirubicin—thyroid cancer	0.000371	0.0122	CcSEcCtD
Idarubicin—Embolism venous—Sorafenib—thyroid cancer	0.000363	0.0119	CcSEcCtD
Idarubicin—Recall phenomenon—Doxorubicin—thyroid cancer	0.000361	0.0119	CcSEcCtD
Idarubicin—Tachyarrhythmia—Doxorubicin—thyroid cancer	0.000343	0.0113	CcSEcCtD
Idarubicin—Myelodysplastic syndrome—Epirubicin—thyroid cancer	0.000338	0.0111	CcSEcCtD
Idarubicin—Mucosal inflammation—Sorafenib—thyroid cancer	0.000331	0.0109	CcSEcCtD
Idarubicin—Myelodysplastic syndrome—Doxorubicin—thyroid cancer	0.000312	0.0103	CcSEcCtD
Idarubicin—Alopecia reversible—Epirubicin—thyroid cancer	0.000298	0.00979	CcSEcCtD
Idarubicin—Septicemia—Epirubicin—thyroid cancer	0.000298	0.00979	CcSEcCtD
Idarubicin—Cardiotoxicity—Epirubicin—thyroid cancer	0.000288	0.00944	CcSEcCtD
Idarubicin—Embolism—Sorafenib—thyroid cancer	0.000286	0.00937	CcSEcCtD
Idarubicin—TOP2A—Erlotinib—Vandetanib—thyroid cancer	0.000283	0.347	CbGdCrCtD
Idarubicin—Myocarditis—Epirubicin—thyroid cancer	0.000278	0.00911	CcSEcCtD
Idarubicin—Alopecia reversible—Doxorubicin—thyroid cancer	0.000276	0.00906	CcSEcCtD
Idarubicin—Septicemia—Doxorubicin—thyroid cancer	0.000276	0.00906	CcSEcCtD
Idarubicin—Cardiotoxicity—Doxorubicin—thyroid cancer	0.000266	0.00873	CcSEcCtD
Idarubicin—Colitis—Vandetanib—thyroid cancer	0.000261	0.00856	CcSEcCtD
Idarubicin—Myocarditis—Doxorubicin—thyroid cancer	0.000257	0.00843	CcSEcCtD
Idarubicin—Leukaemia—Epirubicin—thyroid cancer	0.000252	0.00825	CcSEcCtD
Idarubicin—Neoplasm—Vandetanib—thyroid cancer	0.000246	0.00806	CcSEcCtD
Idarubicin—Sepsis—Vandetanib—thyroid cancer	0.000236	0.00774	CcSEcCtD
Idarubicin—Leukaemia—Doxorubicin—thyroid cancer	0.000233	0.00764	CcSEcCtD
Idarubicin—Septic shock—Epirubicin—thyroid cancer	0.000224	0.00736	CcSEcCtD
Idarubicin—Thromboembolism—Epirubicin—thyroid cancer	0.000213	0.00699	CcSEcCtD
Idarubicin—Atrial fibrillation—Vandetanib—thyroid cancer	0.000208	0.00683	CcSEcCtD
Idarubicin—Septic shock—Doxorubicin—thyroid cancer	0.000208	0.00681	CcSEcCtD
Idarubicin—Thromboembolism—Doxorubicin—thyroid cancer	0.000197	0.00647	CcSEcCtD
Idarubicin—TOP2A—Afatinib—Vandetanib—thyroid cancer	0.000185	0.227	CbGdCrCtD
Idarubicin—Dehydration—Vandetanib—thyroid cancer	0.000183	0.00602	CcSEcCtD
Idarubicin—Sinus tachycardia—Epirubicin—thyroid cancer	0.000168	0.00552	CcSEcCtD
Idarubicin—Neoplasm—Sorafenib—thyroid cancer	0.000166	0.00544	CcSEcCtD
Idarubicin—TOP2A—Gefitinib—Vandetanib—thyroid cancer	0.000162	0.199	CbGdCrCtD
Idarubicin—Neutropenia—Vandetanib—thyroid cancer	0.000159	0.00523	CcSEcCtD
Idarubicin—Pericarditis—Epirubicin—thyroid cancer	0.000157	0.00514	CcSEcCtD
Idarubicin—Sinus tachycardia—Doxorubicin—thyroid cancer	0.000156	0.00511	CcSEcCtD
Idarubicin—Hepatic function abnormal—Sorafenib—thyroid cancer	0.000152	0.005	CcSEcCtD
Idarubicin—Stomatitis—Vandetanib—thyroid cancer	0.000148	0.00486	CcSEcCtD
Idarubicin—Cardiac failure congestive—Sorafenib—thyroid cancer	0.000147	0.00482	CcSEcCtD
Idarubicin—Pericarditis—Doxorubicin—thyroid cancer	0.000145	0.00476	CcSEcCtD
Idarubicin—Myelosuppression—Epirubicin—thyroid cancer	0.000145	0.00474	CcSEcCtD
Idarubicin—Haemoglobin—Vandetanib—thyroid cancer	0.000137	0.0045	CcSEcCtD
Idarubicin—Haemorrhage—Vandetanib—thyroid cancer	0.000136	0.00448	CcSEcCtD
Idarubicin—Urinary tract disorder—Vandetanib—thyroid cancer	0.000135	0.00442	CcSEcCtD
Idarubicin—Embolism venous—Epirubicin—thyroid cancer	0.000134	0.00441	CcSEcCtD
Idarubicin—Bundle branch block—Epirubicin—thyroid cancer	0.000134	0.00441	CcSEcCtD
Idarubicin—Urethral disorder—Vandetanib—thyroid cancer	0.000134	0.00439	CcSEcCtD
Idarubicin—Myelosuppression—Doxorubicin—thyroid cancer	0.000134	0.00439	CcSEcCtD
Idarubicin—Cardiomyopathy—Epirubicin—thyroid cancer	0.000132	0.00434	CcSEcCtD
Idarubicin—Bundle branch block—Doxorubicin—thyroid cancer	0.000124	0.00408	CcSEcCtD
Idarubicin—Embolism venous—Doxorubicin—thyroid cancer	0.000124	0.00408	CcSEcCtD
Idarubicin—Angiopathy—Vandetanib—thyroid cancer	0.000124	0.00406	CcSEcCtD
Idarubicin—Dehydration—Sorafenib—thyroid cancer	0.000124	0.00406	CcSEcCtD
Idarubicin—Cardiomyopathy—Doxorubicin—thyroid cancer	0.000123	0.00402	CcSEcCtD
Idarubicin—Mucosal inflammation—Epirubicin—thyroid cancer	0.000122	0.00402	CcSEcCtD
Idarubicin—Local reaction—Epirubicin—thyroid cancer	0.000122	0.00402	CcSEcCtD
Idarubicin—Arrhythmia—Vandetanib—thyroid cancer	0.000122	0.004	CcSEcCtD
Idarubicin—Alopecia—Vandetanib—thyroid cancer	0.000121	0.00396	CcSEcCtD
Idarubicin—Malnutrition—Vandetanib—thyroid cancer	0.000119	0.0039	CcSEcCtD
Idarubicin—Skin hyperpigmentation—Epirubicin—thyroid cancer	0.000114	0.00374	CcSEcCtD
Idarubicin—Local reaction—Doxorubicin—thyroid cancer	0.000113	0.00372	CcSEcCtD
Idarubicin—Mucosal inflammation—Doxorubicin—thyroid cancer	0.000113	0.00372	CcSEcCtD
Idarubicin—Febrile neutropenia—Epirubicin—thyroid cancer	0.000113	0.0037	CcSEcCtD
Idarubicin—Neutropenia—Sorafenib—thyroid cancer	0.000108	0.00353	CcSEcCtD
Idarubicin—Embolism—Epirubicin—thyroid cancer	0.000106	0.00346	CcSEcCtD
Idarubicin—Skin hyperpigmentation—Doxorubicin—thyroid cancer	0.000105	0.00346	CcSEcCtD
Idarubicin—Febrile neutropenia—Doxorubicin—thyroid cancer	0.000104	0.00342	CcSEcCtD
Idarubicin—Convulsion—Vandetanib—thyroid cancer	0.000103	0.00338	CcSEcCtD
Idarubicin—Chest pain—Vandetanib—thyroid cancer	0.000101	0.00332	CcSEcCtD
Idarubicin—Acute coronary syndrome—Sorafenib—thyroid cancer	0.000101	0.00332	CcSEcCtD
Idarubicin—Myocardial infarction—Sorafenib—thyroid cancer	0.000101	0.0033	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.0001	0.0033	CcSEcCtD
Idarubicin—Bone marrow depression—Epirubicin—thyroid cancer	0.0001	0.00329	CcSEcCtD
Idarubicin—Stomatitis—Sorafenib—thyroid cancer	0.0001	0.00328	CcSEcCtD
Idarubicin—Embolism—Doxorubicin—thyroid cancer	9.77e-05	0.0032	CcSEcCtD
Idarubicin—Burning sensation—Epirubicin—thyroid cancer	9.75e-05	0.0032	CcSEcCtD
Idarubicin—Infection—Vandetanib—thyroid cancer	9.63e-05	0.00316	CcSEcCtD
Idarubicin—Thrombocytopenia—Vandetanib—thyroid cancer	9.49e-05	0.00312	CcSEcCtD
Idarubicin—Skin disorder—Vandetanib—thyroid cancer	9.42e-05	0.00309	CcSEcCtD
Idarubicin—Bone marrow depression—Doxorubicin—thyroid cancer	9.29e-05	0.00305	CcSEcCtD
Idarubicin—Haemoglobin—Sorafenib—thyroid cancer	9.25e-05	0.00304	CcSEcCtD
Idarubicin—Haemorrhage—Sorafenib—thyroid cancer	9.21e-05	0.00302	CcSEcCtD
Idarubicin—Urinary tract disorder—Sorafenib—thyroid cancer	9.09e-05	0.00298	CcSEcCtD
Idarubicin—Urethral disorder—Sorafenib—thyroid cancer	9.03e-05	0.00296	CcSEcCtD
Idarubicin—Burning sensation—Doxorubicin—thyroid cancer	9.02e-05	0.00296	CcSEcCtD
Idarubicin—Necrosis—Epirubicin—thyroid cancer	8.63e-05	0.00283	CcSEcCtD
Idarubicin—Flushing—Sorafenib—thyroid cancer	8.55e-05	0.0028	CcSEcCtD
Idarubicin—Decreased appetite—Vandetanib—thyroid cancer	8.43e-05	0.00277	CcSEcCtD
Idarubicin—Angiopathy—Sorafenib—thyroid cancer	8.35e-05	0.00274	CcSEcCtD
Idarubicin—Immune system disorder—Sorafenib—thyroid cancer	8.32e-05	0.00273	CcSEcCtD
Idarubicin—Arrhythmia—Sorafenib—thyroid cancer	8.23e-05	0.0027	CcSEcCtD
Idarubicin—Alopecia—Sorafenib—thyroid cancer	8.14e-05	0.00267	CcSEcCtD
Idarubicin—Malnutrition—Sorafenib—thyroid cancer	8.02e-05	0.00263	CcSEcCtD
Idarubicin—Necrosis—Doxorubicin—thyroid cancer	7.99e-05	0.00262	CcSEcCtD
Idarubicin—Gastrointestinal pain—Vandetanib—thyroid cancer	7.93e-05	0.0026	CcSEcCtD
Idarubicin—Extravasation—Epirubicin—thyroid cancer	7.77e-05	0.00255	CcSEcCtD
Idarubicin—Body temperature increased—Vandetanib—thyroid cancer	7.67e-05	0.00252	CcSEcCtD
Idarubicin—Abdominal pain—Vandetanib—thyroid cancer	7.67e-05	0.00252	CcSEcCtD
Idarubicin—Anaemia—Sorafenib—thyroid cancer	7.41e-05	0.00243	CcSEcCtD
Idarubicin—Hyperuricaemia—Epirubicin—thyroid cancer	7.3e-05	0.0024	CcSEcCtD
Idarubicin—Extravasation—Doxorubicin—thyroid cancer	7.19e-05	0.00236	CcSEcCtD
Idarubicin—Leukopenia—Sorafenib—thyroid cancer	7.17e-05	0.00235	CcSEcCtD
Idarubicin—Ulcer—Epirubicin—thyroid cancer	7.16e-05	0.00235	CcSEcCtD
Idarubicin—Atrioventricular block—Epirubicin—thyroid cancer	6.99e-05	0.00229	CcSEcCtD
Idarubicin—Blood uric acid increased—Epirubicin—thyroid cancer	6.9e-05	0.00226	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	6.78e-05	0.00222	CcSEcCtD
Idarubicin—Hyperuricaemia—Doxorubicin—thyroid cancer	6.76e-05	0.00222	CcSEcCtD
Idarubicin—Diarrhoea—Vandetanib—thyroid cancer	6.63e-05	0.00218	CcSEcCtD
Idarubicin—Ulcer—Doxorubicin—thyroid cancer	6.63e-05	0.00217	CcSEcCtD
Idarubicin—Anaphylactic shock—Sorafenib—thyroid cancer	6.54e-05	0.00215	CcSEcCtD
Idarubicin—Colitis—Epirubicin—thyroid cancer	6.51e-05	0.00213	CcSEcCtD
Idarubicin—Infection—Sorafenib—thyroid cancer	6.5e-05	0.00213	CcSEcCtD
Idarubicin—Atrioventricular block—Doxorubicin—thyroid cancer	6.46e-05	0.00212	CcSEcCtD
Idarubicin—Shock—Sorafenib—thyroid cancer	6.44e-05	0.00211	CcSEcCtD
Idarubicin—Thrombocytopenia—Sorafenib—thyroid cancer	6.4e-05	0.0021	CcSEcCtD
Idarubicin—Blood uric acid increased—Doxorubicin—thyroid cancer	6.38e-05	0.00209	CcSEcCtD
Idarubicin—Skin disorder—Sorafenib—thyroid cancer	6.35e-05	0.00208	CcSEcCtD
Idarubicin—Anorexia—Sorafenib—thyroid cancer	6.24e-05	0.00205	CcSEcCtD
Idarubicin—Oesophagitis—Epirubicin—thyroid cancer	6.19e-05	0.00203	CcSEcCtD
Idarubicin—Vomiting—Vandetanib—thyroid cancer	6.17e-05	0.00202	CcSEcCtD
Idarubicin—Neoplasm—Epirubicin—thyroid cancer	6.13e-05	0.00201	CcSEcCtD
Idarubicin—Rash—Vandetanib—thyroid cancer	6.11e-05	0.00201	CcSEcCtD
Idarubicin—Dermatitis—Vandetanib—thyroid cancer	6.11e-05	0.002	CcSEcCtD
Idarubicin—Headache—Vandetanib—thyroid cancer	6.08e-05	0.00199	CcSEcCtD
Idarubicin—Colitis—Doxorubicin—thyroid cancer	6.02e-05	0.00198	CcSEcCtD
Idarubicin—Sepsis—Epirubicin—thyroid cancer	5.88e-05	0.00193	CcSEcCtD
Idarubicin—Nausea—Vandetanib—thyroid cancer	5.76e-05	0.00189	CcSEcCtD
Idarubicin—Oesophagitis—Doxorubicin—thyroid cancer	5.73e-05	0.00188	CcSEcCtD
Idarubicin—Phlebitis—Epirubicin—thyroid cancer	5.71e-05	0.00187	CcSEcCtD
Idarubicin—Decreased appetite—Sorafenib—thyroid cancer	5.69e-05	0.00187	CcSEcCtD
Idarubicin—Thrombophlebitis—Epirubicin—thyroid cancer	5.68e-05	0.00186	CcSEcCtD
Idarubicin—Neoplasm—Doxorubicin—thyroid cancer	5.67e-05	0.00186	CcSEcCtD
Idarubicin—Hepatic function abnormal—Epirubicin—thyroid cancer	5.63e-05	0.00185	CcSEcCtD
Idarubicin—Sepsis—Doxorubicin—thyroid cancer	5.44e-05	0.00179	CcSEcCtD
Idarubicin—Cardiac failure congestive—Epirubicin—thyroid cancer	5.42e-05	0.00178	CcSEcCtD
Idarubicin—Gastrointestinal pain—Sorafenib—thyroid cancer	5.35e-05	0.00176	CcSEcCtD
Idarubicin—Phlebitis—Doxorubicin—thyroid cancer	5.28e-05	0.00173	CcSEcCtD
Idarubicin—Hot flush—Epirubicin—thyroid cancer	5.26e-05	0.00173	CcSEcCtD
Idarubicin—Thrombophlebitis—Doxorubicin—thyroid cancer	5.26e-05	0.00173	CcSEcCtD
Idarubicin—Menopausal symptoms—Epirubicin—thyroid cancer	5.21e-05	0.00171	CcSEcCtD
Idarubicin—Hepatic function abnormal—Doxorubicin—thyroid cancer	5.21e-05	0.00171	CcSEcCtD
Idarubicin—Urticaria—Sorafenib—thyroid cancer	5.2e-05	0.00171	CcSEcCtD
Idarubicin—Abdominal pain—Sorafenib—thyroid cancer	5.17e-05	0.0017	CcSEcCtD
Idarubicin—Body temperature increased—Sorafenib—thyroid cancer	5.17e-05	0.0017	CcSEcCtD
Idarubicin—Cardiac failure congestive—Doxorubicin—thyroid cancer	5.02e-05	0.00165	CcSEcCtD
Idarubicin—Hot flush—Doxorubicin—thyroid cancer	4.87e-05	0.0016	CcSEcCtD
Idarubicin—Menopausal symptoms—Doxorubicin—thyroid cancer	4.82e-05	0.00158	CcSEcCtD
Idarubicin—Hypersensitivity—Sorafenib—thyroid cancer	4.82e-05	0.00158	CcSEcCtD
Idarubicin—TOP2A—Daunorubicin—Epirubicin—thyroid cancer	4.8e-05	0.0589	CbGdCrCtD
Idarubicin—TOP2A—Doxorubicin—Epirubicin—thyroid cancer	4.8e-05	0.0589	CbGdCrCtD
Idarubicin—Dehydration—Epirubicin—thyroid cancer	4.57e-05	0.0015	CcSEcCtD
Idarubicin—Diarrhoea—Sorafenib—thyroid cancer	4.48e-05	0.00147	CcSEcCtD
Idarubicin—TOP2A—Epirubicin—Doxorubicin—thyroid cancer	4.44e-05	0.0545	CbGdCrCtD
Idarubicin—TOP2A—Daunorubicin—Doxorubicin—thyroid cancer	4.44e-05	0.0545	CbGdCrCtD
Idarubicin—Dehydration—Doxorubicin—thyroid cancer	4.23e-05	0.00139	CcSEcCtD
Idarubicin—Vomiting—Sorafenib—thyroid cancer	4.16e-05	0.00136	CcSEcCtD
Idarubicin—Rash—Sorafenib—thyroid cancer	4.12e-05	0.00135	CcSEcCtD
Idarubicin—Dermatitis—Sorafenib—thyroid cancer	4.12e-05	0.00135	CcSEcCtD
Idarubicin—Headache—Sorafenib—thyroid cancer	4.1e-05	0.00134	CcSEcCtD
Idarubicin—Pancytopenia—Epirubicin—thyroid cancer	4.04e-05	0.00132	CcSEcCtD
Idarubicin—Neutropenia—Epirubicin—thyroid cancer	3.98e-05	0.0013	CcSEcCtD
Idarubicin—Nausea—Sorafenib—thyroid cancer	3.89e-05	0.00127	CcSEcCtD
Idarubicin—Pancytopenia—Doxorubicin—thyroid cancer	3.74e-05	0.00123	CcSEcCtD
Idarubicin—Stomatitis—Epirubicin—thyroid cancer	3.69e-05	0.00121	CcSEcCtD
Idarubicin—Neutropenia—Doxorubicin—thyroid cancer	3.68e-05	0.00121	CcSEcCtD
Idarubicin—Haemoglobin—Epirubicin—thyroid cancer	3.42e-05	0.00112	CcSEcCtD
Idarubicin—Stomatitis—Doxorubicin—thyroid cancer	3.42e-05	0.00112	CcSEcCtD
Idarubicin—Haemorrhage—Epirubicin—thyroid cancer	3.4e-05	0.00112	CcSEcCtD
Idarubicin—Urinary tract disorder—Epirubicin—thyroid cancer	3.36e-05	0.0011	CcSEcCtD
Idarubicin—Urethral disorder—Epirubicin—thyroid cancer	3.34e-05	0.00109	CcSEcCtD
Idarubicin—Haemoglobin—Doxorubicin—thyroid cancer	3.16e-05	0.00104	CcSEcCtD
Idarubicin—Flushing—Epirubicin—thyroid cancer	3.16e-05	0.00104	CcSEcCtD
Idarubicin—Haemorrhage—Doxorubicin—thyroid cancer	3.15e-05	0.00103	CcSEcCtD
Idarubicin—Urinary tract disorder—Doxorubicin—thyroid cancer	3.11e-05	0.00102	CcSEcCtD
Idarubicin—Angiopathy—Epirubicin—thyroid cancer	3.09e-05	0.00101	CcSEcCtD
Idarubicin—Urethral disorder—Doxorubicin—thyroid cancer	3.09e-05	0.00101	CcSEcCtD
Idarubicin—Immune system disorder—Epirubicin—thyroid cancer	3.07e-05	0.00101	CcSEcCtD
Idarubicin—Chills—Epirubicin—thyroid cancer	3.05e-05	0.001	CcSEcCtD
Idarubicin—Arrhythmia—Epirubicin—thyroid cancer	3.04e-05	0.000997	CcSEcCtD
Idarubicin—Alopecia—Epirubicin—thyroid cancer	3.01e-05	0.000987	CcSEcCtD
Idarubicin—Malnutrition—Epirubicin—thyroid cancer	2.96e-05	0.000972	CcSEcCtD
Idarubicin—Flushing—Doxorubicin—thyroid cancer	2.92e-05	0.000959	CcSEcCtD
Idarubicin—Angiopathy—Doxorubicin—thyroid cancer	2.86e-05	0.000937	CcSEcCtD
Idarubicin—Immune system disorder—Doxorubicin—thyroid cancer	2.84e-05	0.000933	CcSEcCtD
Idarubicin—Chills—Doxorubicin—thyroid cancer	2.83e-05	0.000927	CcSEcCtD
Idarubicin—Arrhythmia—Doxorubicin—thyroid cancer	2.81e-05	0.000923	CcSEcCtD
Idarubicin—Alopecia—Doxorubicin—thyroid cancer	2.78e-05	0.000913	CcSEcCtD
Idarubicin—Malnutrition—Doxorubicin—thyroid cancer	2.74e-05	0.000899	CcSEcCtD
Idarubicin—Anaemia—Epirubicin—thyroid cancer	2.74e-05	0.000898	CcSEcCtD
Idarubicin—Leukopenia—Epirubicin—thyroid cancer	2.65e-05	0.00087	CcSEcCtD
Idarubicin—Convulsion—Epirubicin—thyroid cancer	2.57e-05	0.000842	CcSEcCtD
Idarubicin—Anaemia—Doxorubicin—thyroid cancer	2.53e-05	0.000831	CcSEcCtD
Idarubicin—Chest pain—Epirubicin—thyroid cancer	2.52e-05	0.000827	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	2.5e-05	0.000822	CcSEcCtD
Idarubicin—Leukopenia—Doxorubicin—thyroid cancer	2.45e-05	0.000805	CcSEcCtD
Idarubicin—Anaphylactic shock—Epirubicin—thyroid cancer	2.42e-05	0.000793	CcSEcCtD
Idarubicin—Infection—Epirubicin—thyroid cancer	2.4e-05	0.000788	CcSEcCtD
Idarubicin—Shock—Epirubicin—thyroid cancer	2.38e-05	0.00078	CcSEcCtD
Idarubicin—Convulsion—Doxorubicin—thyroid cancer	2.37e-05	0.000779	CcSEcCtD
Idarubicin—Thrombocytopenia—Epirubicin—thyroid cancer	2.37e-05	0.000777	CcSEcCtD
Idarubicin—Skin disorder—Epirubicin—thyroid cancer	2.35e-05	0.00077	CcSEcCtD
Idarubicin—Chest pain—Doxorubicin—thyroid cancer	2.33e-05	0.000766	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	2.32e-05	0.00076	CcSEcCtD
Idarubicin—Anorexia—Epirubicin—thyroid cancer	2.3e-05	0.000756	CcSEcCtD
Idarubicin—Anaphylactic shock—Doxorubicin—thyroid cancer	2.24e-05	0.000734	CcSEcCtD
Idarubicin—Infection—Doxorubicin—thyroid cancer	2.22e-05	0.000729	CcSEcCtD
Idarubicin—Shock—Doxorubicin—thyroid cancer	2.2e-05	0.000722	CcSEcCtD
Idarubicin—Thrombocytopenia—Doxorubicin—thyroid cancer	2.19e-05	0.000719	CcSEcCtD
Idarubicin—Skin disorder—Doxorubicin—thyroid cancer	2.17e-05	0.000713	CcSEcCtD
Idarubicin—Anorexia—Doxorubicin—thyroid cancer	2.13e-05	0.0007	CcSEcCtD
Idarubicin—Decreased appetite—Epirubicin—thyroid cancer	2.1e-05	0.00069	CcSEcCtD
Idarubicin—Gastrointestinal pain—Epirubicin—thyroid cancer	1.98e-05	0.000649	CcSEcCtD
Idarubicin—Decreased appetite—Doxorubicin—thyroid cancer	1.94e-05	0.000638	CcSEcCtD
Idarubicin—Urticaria—Epirubicin—thyroid cancer	1.92e-05	0.00063	CcSEcCtD
Idarubicin—Abdominal pain—Epirubicin—thyroid cancer	1.91e-05	0.000627	CcSEcCtD
Idarubicin—Body temperature increased—Epirubicin—thyroid cancer	1.91e-05	0.000627	CcSEcCtD
Idarubicin—Gastrointestinal pain—Doxorubicin—thyroid cancer	1.83e-05	0.0006	CcSEcCtD
Idarubicin—Hypersensitivity—Epirubicin—thyroid cancer	1.78e-05	0.000584	CcSEcCtD
Idarubicin—Urticaria—Doxorubicin—thyroid cancer	1.78e-05	0.000583	CcSEcCtD
Idarubicin—Abdominal pain—Doxorubicin—thyroid cancer	1.77e-05	0.00058	CcSEcCtD
Idarubicin—Body temperature increased—Doxorubicin—thyroid cancer	1.77e-05	0.00058	CcSEcCtD
Idarubicin—Diarrhoea—Epirubicin—thyroid cancer	1.65e-05	0.000543	CcSEcCtD
Idarubicin—Hypersensitivity—Doxorubicin—thyroid cancer	1.65e-05	0.000541	CcSEcCtD
Idarubicin—Vomiting—Epirubicin—thyroid cancer	1.54e-05	0.000504	CcSEcCtD
Idarubicin—Diarrhoea—Doxorubicin—thyroid cancer	1.53e-05	0.000502	CcSEcCtD
Idarubicin—Rash—Epirubicin—thyroid cancer	1.52e-05	0.0005	CcSEcCtD
Idarubicin—Dermatitis—Epirubicin—thyroid cancer	1.52e-05	0.0005	CcSEcCtD
Idarubicin—Headache—Epirubicin—thyroid cancer	1.51e-05	0.000497	CcSEcCtD
Idarubicin—Nausea—Epirubicin—thyroid cancer	1.44e-05	0.000471	CcSEcCtD
Idarubicin—Vomiting—Doxorubicin—thyroid cancer	1.42e-05	0.000467	CcSEcCtD
Idarubicin—Rash—Doxorubicin—thyroid cancer	1.41e-05	0.000463	CcSEcCtD
Idarubicin—Dermatitis—Doxorubicin—thyroid cancer	1.41e-05	0.000462	CcSEcCtD
Idarubicin—Headache—Doxorubicin—thyroid cancer	1.4e-05	0.00046	CcSEcCtD
Idarubicin—Nausea—Doxorubicin—thyroid cancer	1.33e-05	0.000436	CcSEcCtD
